Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)
South Korea
· Delayed Price · Currency is KRW 3,165.00
-95.00 (-2.91%)
At close: Apr 28, 2026
Vivozon Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -32,424 | -9,982 | -3,357 | -39,906 | -69,457 | Upgrade
|
| Depreciation & Amortization | 4,427 | 3,564 | 3,228 | 3,643 | 5,552 | Upgrade
|
| Loss (Gain) From Sale of Assets | 89.46 | -101.89 | 521 | -278.96 | 229.9 | Upgrade
|
| Asset Writedown & Restructuring Costs | 4,748 | 1,051 | 32.62 | 6,183 | 35,847 | Upgrade
|
| Loss (Gain) From Sale of Investments | 1,744 | -7.32 | 812.22 | 1,602 | 13,674 | Upgrade
|
| Loss (Gain) on Equity Investments | 4,797 | 1,470 | 2,821 | 3,240 | 691.35 | Upgrade
|
| Stock-Based Compensation | 726.45 | 339.88 | - | -51.01 | 277.47 | Upgrade
|
| Provision & Write-off of Bad Debts | -266.61 | -160.23 | -2,111 | 4,910 | 1,163 | Upgrade
|
| Other Operating Activities | 5,393 | 10,330 | 5,497 | 13,266 | 3,708 | Upgrade
|
| Change in Accounts Receivable | 3,179 | -3,228 | -4,419 | -2,278 | -2,734 | Upgrade
|
| Change in Inventory | 2,057 | -6,912 | -3,665 | 2,750 | -3,756 | Upgrade
|
| Change in Accounts Payable | -8,518 | 9,397 | 4,719 | 835.48 | -81.21 | Upgrade
|
| Change in Other Net Operating Assets | 7,178 | -28.31 | -1,088 | 2,760 | -2,611 | Upgrade
|
| Operating Cash Flow | -6,869 | 5,731 | 2,992 | -3,323 | -17,496 | Upgrade
|
| Operating Cash Flow Growth | - | 91.57% | - | - | - | Upgrade
|
| Capital Expenditures | -1,412 | -8,450 | -4,523 | -6,491 | -10,111 | Upgrade
|
| Sale of Property, Plant & Equipment | 12.27 | 89.5 | 9,410 | 645 | -233.64 | Upgrade
|
| Sale (Purchase) of Intangibles | -801 | -2,027 | -2,066 | -2,008 | -1,527 | Upgrade
|
| Investment in Securities | 191.34 | 6,170 | 13,777 | -26,880 | -24,261 | Upgrade
|
| Other Investing Activities | 1.88 | -666.68 | 441.38 | -169.41 | -9,196 | Upgrade
|
| Investing Cash Flow | 4.94 | -6,373 | 19,309 | -34,552 | -47,128 | Upgrade
|
| Short-Term Debt Issued | 7,341 | 1,459 | 7,600 | 4,020 | 18,480 | Upgrade
|
| Long-Term Debt Issued | - | 3,000 | - | 3,100 | 10,000 | Upgrade
|
| Total Debt Issued | 7,341 | 4,459 | 7,600 | 7,120 | 28,480 | Upgrade
|
| Short-Term Debt Repaid | -1,612 | -312 | -17,900 | -6,000 | -11,300 | Upgrade
|
| Long-Term Debt Repaid | -1,254 | -3,361 | -6,924 | -28,396 | -1,590 | Upgrade
|
| Total Debt Repaid | -2,866 | -3,673 | -24,824 | -34,396 | -12,890 | Upgrade
|
| Net Debt Issued (Repaid) | 4,475 | 786.05 | -17,224 | -27,276 | 15,590 | Upgrade
|
| Issuance of Common Stock | - | - | 2,059 | 58,171 | 0.02 | Upgrade
|
| Repurchase of Common Stock | - | - | -18.19 | - | - | Upgrade
|
| Other Financing Activities | -997.18 | -1,605 | -1,476 | -4,503 | -2,075 | Upgrade
|
| Financing Cash Flow | 3,477 | -818.68 | -16,659 | 26,391 | 13,515 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0 | -0.9 | -6.1 | 36.68 | 576.64 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | - | - | - | - | Upgrade
|
| Net Cash Flow | -3,387 | -1,462 | 5,635 | -11,448 | -50,533 | Upgrade
|
| Free Cash Flow | -8,281 | -2,719 | -1,532 | -9,814 | -27,608 | Upgrade
|
| Free Cash Flow Margin | -13.95% | -3.10% | -2.15% | -19.03% | -47.96% | Upgrade
|
| Free Cash Flow Per Share | -167.28 | -56.93 | -32.10 | -225.59 | -846.59 | Upgrade
|
| Cash Interest Paid | 997.18 | 1,574 | 1,464 | 3,288 | 1,723 | Upgrade
|
| Cash Income Tax Paid | 74.82 | 58.28 | -3.43 | -45.67 | 36.03 | Upgrade
|
| Levered Free Cash Flow | -5,751 | -4,053 | -4,763 | -2,283 | -26,841 | Upgrade
|
| Unlevered Free Cash Flow | -4,374 | -2,644 | -2,948 | 1,012 | -22,280 | Upgrade
|
| Change in Working Capital | 3,897 | -771.51 | -4,453 | 4,067 | -9,182 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.